Halozyme Therapeutics, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; unaudited. Halozyme is a biotechnology company developing oncology therapies and licensing its ENHANZE subcutaneous-delivery technology. Unless noted, financial amounts are in millions of dollars.
Financial performance and position
| Metric | Q1 2016 | Q1 2015 / prior balance |
|---|---|---|
| Total revenue | $42.5 | $18.7 |
| Operating loss | $(16.2) | $(13.9) |
| Net loss | $(19.8) | $(15.1) |
| Basic and diluted loss per share | $(0.16) | $(0.12) |
| Operating cash used | $(13.0) | $(13.8) |
| Cash and cash equivalents | $69.1 | $43.3 at Dec. 31, 2015 |
| Available-for-sale marketable securities | $169.5 | $65.0 at Dec. 31, 2015 |
| Long-term debt, current and noncurrent | $196.0 | $49.8 at Dec. 31, 2015 |
| Stockholders’ equity | $29.5 | $43.0 at Dec. 31, 2015 |
Product sales were $12.9 million, royalties $11.4 million, and collaborative-agreement revenue $18.2 million. Product-sales gross profit was approximately $5.2 million, or about 40% of product sales. Operating expenses were $58.7 million, including $40.1 million of R&D and $10.8 million of SG&A. Interest expense was $3.9 million.
Cash, cash equivalents and marketable securities totaled approximately $238.6 million at quarter end. Investing cash outflow was $105.6 million, largely reflecting net purchases of marketable securities; financing provided $144.4 million, chiefly from the royalty-backed loan. Current assets were $297.0 million and current liabilities $64.2 million.
Material changes versus prior period
- Revenue rose 128%, principally reflecting $33.0 million of license-fee revenue recognized under the Lilly collaboration and $6.0 million of milestone or event-based collaboration payments. Royalty revenue increased mainly because of higher Roche Herceptin SC sales.
- R&D expense increased $23.4 million, primarily from expanded PEGPH20 clinical activity and ENHANZE-related manufacturing. Management expects R&D to rise as PEGPH20 development continues; SG&A is expected to increase moderately.
- Net loss widened by $4.7 million despite higher revenue, as operating expenses and interest expense increased.
- In January, the company borrowed $150 million through a royalty-backed financing subsidiary, secured by specified Roche and Baxalta royalties. The loan bears interest at 8.75% plus capped three-month LIBOR; the reported Q1 rate was 9.45%. Management estimated repayment in Q1 2020, subject to royalty performance. The separate Oxford/SVB loan had a $46.0 million outstanding balance and matures January 2018.
Outlook, commentary and risks
- Management said existing cash, cash equivalents and marketable securities should fund operations for at least the next 12 months. It anticipated a $45–$65 million increase in cash and cash equivalents during 2016, dependent on program progress, manufacturing scale-up, milestones and royalties. The filing cautions that available resources may not fund operations until profitability, if ever, and additional financing may be needed.
- PEGPH20 Phase 3 Study 109-301 in previously untreated stage IV pancreatic cancer began dosing in March 2016. The company projected mature PFS and response-rate results from Phase 2 Study 109-202 in Q4 2016. The FDA-approved investigational device exemption for the Ventana companion diagnostic supports patient selection for Study 301.
- PEGPH20 development remains subject to safety and regulatory uncertainty. A prior Study 202 clinical hold followed a possible imbalance in thromboembolic events; the revised trial uses anticoagulant prophylaxis and continues safety monitoring. Further safety concerns could halt studies.
- Key business risks include clinical-trial and regulatory failure or delay, dependence on collaborators for development and commercialization, third-party manufacturing and supply, rHuPH20-related safety or regulatory issues, competition, and financing and debt obligations. Collaborators may terminate agreements, and royalty-backed loan repayment depends on royalties received.
- The company reported no material legal proceedings and stated it was in compliance with material covenants on both loan facilities. Disclosure controls were assessed as effective; no material change in internal control was reported.
Important facts for investors to verify
- Whether Q4 2016 Study 109-202 results, subsequent safety findings, and Study 109-301 progress support the projected clinical and regulatory path.
- Whether Roche and Baxalta product sales sustain royalties sufficient to support the royalty-backed loan’s estimated repayment timing.
- How much of the reported revenue increase reflects recurring product sales and royalties versus license fees and milestone payments.
- Actual operating cash use, R&D spending, financing needs, and progress against management’s 2016 cash outlook.
- Any updates to trial safety, companion-diagnostic requirements, manufacturing capacity, or collaborator development and commercialization plans.